These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 1892748

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase.
    Fruehauf JP, Zonis S, al-Bassam M, Kyshtoobayeva A, Dasgupta C, Milovanovic T, Parker RJ, Buzaid AC.
    Pigment Cell Res; 1997 Aug; 10(4):236-49. PubMed ID: 9263331
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF, Koberle B, Masters JR, Kelland LR.
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [Abstract] [Full Text] [Related]

  • 26. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
    Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC, Ozols RF.
    Cancer Res; 1987 Jan 15; 47(2):414-8. PubMed ID: 3539322
    [Abstract] [Full Text] [Related]

  • 27. Effect of glutathione depletion on the cytotoxicity of cisplatin and iproplatin in a human melanoma cell line.
    Pendyala L, Perez R, Weinstein A, Zdanowicz J, Creaven PJ.
    Cancer Chemother Pharmacol; 1997 Jan 15; 40(1):38-44. PubMed ID: 9137527
    [Abstract] [Full Text] [Related]

  • 28. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR.
    Cancer Res; 1993 Jun 01; 53(11):2581-6. PubMed ID: 8388318
    [Abstract] [Full Text] [Related]

  • 29. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.
    Jones M, Siracky J, Kelland LR, Harrap KR.
    Br J Cancer; 1993 Jan 01; 67(1):24-9. PubMed ID: 8427780
    [Abstract] [Full Text] [Related]

  • 30. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
    Anderson CP, Reynolds CP.
    Bone Marrow Transplant; 2002 Aug 01; 30(3):135-40. PubMed ID: 12189530
    [Abstract] [Full Text] [Related]

  • 31. Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.
    Kelland LR, Jones M, Abel G, Valenti M, Gwynne J, Harrap KR.
    Cancer Chemother Pharmacol; 1992 Aug 01; 30(1):43-50. PubMed ID: 1586979
    [Abstract] [Full Text] [Related]

  • 32. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
    Lai SL, Hwang J, Perng RP, Whang-Peng J.
    Oncol Res; 1995 Aug 01; 7(1):31-8. PubMed ID: 7549042
    [Abstract] [Full Text] [Related]

  • 33. Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines.
    Kido Y, Khokhar AR, Siddik ZH.
    Anticancer Drugs; 1993 Apr 01; 4(2):251-8. PubMed ID: 8490203
    [Abstract] [Full Text] [Related]

  • 34. DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines.
    Mellish KJ, Barnard CF, Murrer BA, Kelland LR.
    Int J Cancer; 1995 Sep 15; 62(6):717-23. PubMed ID: 7558420
    [Abstract] [Full Text] [Related]

  • 35. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
    Kelland LR, Mistry P, Abel G, Loh SY, O'Neill CF, Murrer BA, Harrap KR.
    Cancer Res; 1992 Jul 15; 52(14):3857-64. PubMed ID: 1617660
    [Abstract] [Full Text] [Related]

  • 36. Enhancement of melphalan activity by buthionine sulfoximine and electroporation in melanoma cells.
    Ongaro A, Pellati A, De Mattei M, De Terlizzi F, Rossi CR, Campana LG.
    Anticancer Drugs; 2015 Mar 15; 26(3):284-92. PubMed ID: 25514113
    [Abstract] [Full Text] [Related]

  • 37. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W, Chaney SG.
    Cancer Res; 1993 Feb 15; 53(4):799-805. PubMed ID: 8428361
    [Abstract] [Full Text] [Related]

  • 38. Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.
    Raynaud FI, Odell DE, Kelland LR.
    Br J Cancer; 1996 Aug 15; 74(3):380-6. PubMed ID: 8695352
    [Abstract] [Full Text] [Related]

  • 39. Effect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin C analogues BMY 25282 and BMY 25067.
    Xu BH, Singh SV.
    Cancer Res; 1992 Dec 01; 52(23):6666-70. PubMed ID: 1423311
    [Abstract] [Full Text] [Related]

  • 40. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
    Kramer RA, Greene K, Ahmad S, Vistica DT.
    Cancer Res; 1987 Mar 15; 47(6):1593-7. PubMed ID: 3815359
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.